The Prognostic Role of the Neutrophil-to-Lymphocyte Ratio in XXXX Treated with Chemoradiotherapy.

@entity1 @entity18258 @entity5 @entity189 @entity1544
BACKGROUND: The aim of the study is to investigate the prognostic role of pre-treatment of markers of the systemic inflammatory response (neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and albumin) in @entity1 with @entity189 treated with chemoradiotherapy. METHODS: A total of 251 @entity1 with @entity1544 treated with chemoradiotherapy between 2004 and 2010 were retrospectively identified. NLR, PLR, and albumin were recorded from baseline blood parameters. NLR threshold of >5 and PLR thresholds of  <=150, >150 and  <=300, and >300 were used for analysis. RESULTS: Median follow-up was 46 months (range 9-98). The 3 year overall survival, local control, regional control, and distant control were 70%, 85%, 87%, and 87%, respectively. On multivariate analysis, locoregional control was associated with T stage (HR 3.3 (95% CI 1.5-6.9), P = 0.002) and NLR ( @entity18258 (95% CI 1.1-3.9), P = 0.023). Overall survival was associated with T stage (HR 2.47 (95% CI 1.45-4.2), P = 0.001) and grade (HR 0.61 (95% CI 0.38-0.99), P = 0.048). PLR and albumin were not significantly associated with disease outcomes or survival. CONCLUSIONS: The NLR is an independent prognostic factor for locoregional control in @entity5 treated with chemoradiotherapy.
